ArticleMedical oncology (Northwood, London, England)2011
MCF-7/ADR cells (re-designated NCI/ADR-RES) are not derived from MCF-7 breast cancer cells: a loss for breast cancer multidrug-resistant research.
Article in Medical oncology (Northwood, London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Activity of Didesmethylrocaglamide in High Grade Serous Ovarian Cancer Using Preclinical In Vitro and In Vivo Models.Journal of natural products · 2026Article
- The Effect of Cannabidiol on Cancer-Pathway Genes in Doxorubicin-Sensitive and Resistant Breast Cancer Cells.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Self-Assembling Cyclic Peptide Nanotubes for the Delivery of Doxorubicin into Drug-Resistant Cancer Cells.ACS applied materials & interfaces · 2025Article
- Tolyporphins-Exotic Tetrapyrrole Pigments in a Cyanobacterium-A Review.Molecules (Basel, Switzerland) · 2023Review
- Characterization of Anticancer Effects of the Analogs of DJ4, a Novel Selective Inhibitor of ROCK and MRCK Kinases.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Anticancer Drug Doxorubicin Spontaneously Reacts with GTP and dGTP.Chemical research in toxicology · 2023Article
- Multiomics surface receptor profiling of the NCI-60 tumor cell panel uncovers novel theranostics for cancer immunotherapy.Cancer cell international · 2022Article
- Gibberellin derivative GA-13315 overcomes multidrug resistance in breast cancer by up-regulating BMP6 expression.Frontiers in pharmacology · 2022Article
- Exploring near-infrared absorbing nanocarriers to overcome cancer drug resistance.Cancer drug resistance (Alhambra, Calif.) · 2020Review
- Models used to screen for the treatment of multidrug resistant cancer facilitated by transporter-based efflux.Journal of cancer research and clinical oncology · 2019Review
- Long-Circulating Amphiphilic Doxorubicin for Tumor Mitochondria-Specific Targeting.ACS applied materials & interfaces · 2018Article
- pH-Sensitive Poly(β-amino ester)s Nanocarriers Facilitate the Inhibition of Drug Resistance in Breast Cancer Cells.Nanomaterials (Basel, Switzerland) · 2018Article
- A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model.Molecular neurodegeneration · 2018Article
- A multi-state model of chemoresistance to characterize phenotypic dynamics in breast cancer.Scientific reports · 2018Article
- Targeted production of reactive oxygen species in mitochondria to overcome cancer drug resistance.Nature communications · 2018Article
- Pyronaridine exerts potent cytotoxicity on human breast and hematological cancer cells through induction of apoptosis.PloS one · 2018Article
- Cisplatin Resistant Spheroids Model Clinically Relevant Survival Mechanisms in Ovarian Tumors.PloS one · 2016Article
- Synthesis and antileukemic activities of C1-C10-modified parthenolide analogues.Bioorganic & medicinal chemistry · 2015Article
- Knockdown of c-MET induced apoptosis in ABCB1-overexpressed multidrug-resistance cancer cell lines.Cancer gene therapy · 2015Article
- In Vitro Antimicrobial and Antiproliferative Activity of Amphipterygium adstringens.Evidence-based complementary and alternative medicine : eCAM · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MCF-7/ADR cells have been widely used as a multidrug-resistant breast cancer cell model in cancer research. The origin of MCF-7/ADR has been a matter of debate since MCF-7/ADR cells were re-designated NCI/ADR-RES in 1998. Many recent studies still describe MCF-7/ADR cells as originating from the breast cancer cell line MCF-7. Thus, the real origin of MCF-7/ADR cells remains more unclear. In this study, a new adriamycin (ADR)-resistant cell line MCF-7/ADR' was reproduced using the same procedure employed during the initial establishment of MCF-7/ADR. Since the MCF-7/ADR' cell line was definitely derived from parental MCF-7 cells, we were able to directly compare these cell lines together with MCF-7/ADR using immunocytochemical, morphological, and consecutive DNA fingerprinting analyses to determine the true origin of MCF-7/ADR. Both ADR-resistant cell lines displayed some similar phenotypic characteristics, such as high levels of P-glycoprotein (P-gp) expression, increased vacuolation, abundant filamentous material, and irregular pseudopodia. With increasing concentrations of ADR, the DNA fingerprints of MCF-7/ADR' cells were always identical to the parental MCF-7 cells. However, the DNA fingerprints of MCF-7/ADR cells did not relate to MCF-7 or MCF-7/ADR'. MCF-7/ADR and the breast cancer cell line MCF-7 are not of the same origin. Long-time culture in the presence of ADR does not cause significant changes in DNA fingerprint patterns.
Indexed as
Identifiers
21116879What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.